Johnson & Johnson (NYSE:JNJ) is one of the stocks Jim Cramer offered insights on. Cramer highlighted the company’s latest spin-off plans for one of its divisions, as he commented: “The fastest grower, the best opportunity here would not be Eli Lilly, which has moved a great deal and I still like, but Johnson & Johnson. It’s spinning off its orthopaedics business, DePuy Synthes, something that will immediately raise its price-to-earnings multiple because that business has much slower growth than the core p ...

Johnson & Johnson (NYSE:JNJ) is one of the stocks Jim Cramer talked about recently. Cramer mentioned the stock during the episode and said: “These groups were the salvation of this market when the year of magical investing ended, and the super speculative stocks started coming back to earth, they’re still doing it, followed by the data center plays. These were the groups that saved you. We don’t talk about this migration much, but all you need to know is just to look at the stocks of Merck and Johnson & J ...

Core Viewpoint - Johnson & Johnson (NYSE: JNJ) is focusing on high-growth pharmaceutical sectors while divesting from non-proprietary businesses, particularly in the commoditized artificial joint market, which is seen as a strategic move to enhance its investment appeal [1][2]. Group 1: Company Strategy - Johnson & Johnson is spinning off its commoditized artificial joint business to concentrate on proprietary high-growth pharmaceutical areas, especially in oncology and immunology [2]. - The company is moving away from "everything non-proprietary," indicating a strategic shift towards more innovative and higher-margin products [2]. Group 2: Investment Perspective - Jim Cramer expressed a favorable view of JNJ, suggesting it could be a strong investment alongside Merck, highlighting the company's solid franchise and potential for growth [1]. - Cramer noted that both JNJ and Amgen offer yields greater than 2.7%, making them attractive options for investors looking for stability and growth [2].

Core Insights - Johnson & Johnson (JNJ) is a leading global healthcare conglomerate with a market cap of approximately $500.1 billion, recognized for its extensive portfolio in pharmaceuticals and medical devices [1][2] Financial Performance - JNJ's stock has shown strong performance, gaining 17.6% over the past three months, significantly outperforming the S&P 500 Index, which gained 5.1% in the same period [3] - Year-to-date, JNJ has risen 43.5%, and over the past 52 weeks, it has climbed 34.3%, again surpassing the S&P 500's YTD gains of 15.8% and 13.6% over the past year [4] - In Q3, reported on October 14, JNJ's sales increased by 6.8% year-over-year, with adjusted EPS rising 15.7% annually to $2.80 [5] Strategic Moves - The company is spinning off its slower-growing orthopedics business to focus on higher-margin and faster-growing sectors such as cardiovascular and MedTech, while also enhancing its drug pipeline through acquisitions [5] Market Position - JNJ is categorized as a "mega-cap stock" due to its market cap exceeding $200 billion, reflecting its significant influence and dominance in the drug manufacturing industry [2]

Core Points - Covalon Technologies Ltd. announced its first-ever special cash dividend of C$0.15 per common share, to be paid on November 18, 2025, indicating strong financial performance [1] Financial Performance - The declaration of the special dividend reflects the company's continued success in accelerating the adoption of its unique, patented medical technologies [1]